Clinical Trials · NCT04538352
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- The Cleveland Clinic
- Enrollment
- 60
- Start date
- Jan 2021
- Locations
- 1 site, United States
- Primary endpoint
- Mean Change in HbA1C ≤ 7.5%